| Cell Therapy News 21.15 April 27, 2020 | |
|
|
|
|
TOP STORYInvestigators demonstrated that administration of CAR T cells into the cerebrospinal fluid, alone or in combination with azacytidine, was a highly effective therapy for multiple metastatic mouse models of group 3 medulloblastoma and posterior fossa group A ependymoma. [Nat Med] Abstract |
|
|
|
|
PUBLICATIONS(Ranked by impact factor of the journal)B7-H3.BB.z-CAR T cells administered intracerebroventricularly or intratumorally mediated potent antitumor effects against cerebral atypical teratoid/rhabdoid tumor xenografts in mice, with faster kinetics, greater potency and reduced systemic levels of inflammatory cytokines compared to CAR T cells administered intravenously. [Nat Med] Abstract Scientists used CRISPR-Cas9 to correct a diabetes-causing pathogenic variant in Wolfram syndrome (WS) 1 in induced pluripotent stem cells (iPSCs) derived from a patient with WS. Corrected WS iPSC-derived β cells performed robust dynamic insulin secretion in vitro in response to glucose and reversed preexisting streptozocin-induced diabetes after transplantation into mice. [Sci Transl Med] Abstract | Press Release A Vaccine-Based Nanosystem for Initiating Innate Immunity and Improving Tumor Immunotherapy The authors generated a vaccine-based nanosystem by integrating siRNA for Cd274 into the commercial human papillomavirus L1 protein. This nanosystem had good biosafety and enhanced the therapeutic response rate of anti-tumor immunotherapy. [Nat Commun] Full Article scAAV2-C3 significantly reduced the number of apoptotic retinal ganglion cells and decreased the cells loss in ganglion cell layer after ischemia/reperfusion (I/R) injury, and the I/R injured retinas treated with scAAV2-C3 were the thickest in all I/R groups. [Mol Ther Methods Clin Dev] Abstract | Full Article | Graphical Abstract Investigators designed a hydrogel that activated notch signaling through 3D presentation of the notch ligand delta-1 to use as an injectate for transplanting human stem cell-derived cardiomyocytes (hESC-CMs) into the infarcted rat myocardium. After four weeks, hESC-CM proliferation increased two-fold and resulted in a three-fold increase in graft size with the delta-1 hydrogel compared to controls. [Mol Ther Methods Clin Dev] Abstract | Full Article | Graphical Abstract Dextran sulfate sodium (DSS)-induced colitic mice treated with adipose-derived mesenchymal stem cells (aMSCs) showed significant reduction in their colitic disease activity index during the second DSS challenge when compared to non-aMSC-treated DSS-induced colitic mice. [J Crohns Colitis] Full Article Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) inhibited schizophrenia-relevant and the neuroinflammatory changes. The main mechanism of hUC-MSCs was associated with the induction of Tregs and production of the anti-inflammatory cytokine, IL-10, in periphery. [Transl Psychiatry] Full Article Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators Transplantation of human myogenic progenitors derived from endogenous activation of PAX7 into immunodeficient mice resulted in a greater number of human dystrophin+ myofibers compared with exogenous PAX7 overexpression. [Stem Cell Reports] Full Article | Graphical Abstract Platelet-rich plasma application significantly enhanced the regeneration capacity of muscle-derived mesenchymal stem cells (M-MSCs) in a large bone defect via promoting the migration and proliferation of M-MSCs, and also inducing the osteogenic differentiation. [Sci Rep] Full Article Scientists evaluated the capability of AAV2.retro to deliver disease-related gene cargo to biologically-relevant nonhuman primate brain circuits by packaging a fragment of human mutant HTT, the causative gene mutation in Huntington’s disease. [Sci Rep] Full Article AAV-Mediated Cardiac Gene Transfer of Wild-Type Desmin in Mouse Models for Recessive Desminopathies Researchers investigated the effects of AAV-mediated cardiac wild-type desmin expression in homozygous desmin knockout and homozygous R349P desmin knockin mice. [Gene Ther] Full Article Subscribe to one of our other 19 science newsletters such as Mesenchymal Cell News & ESC & iPSC News. |
|
|
|
|
REVIEWSMesenchymal Stem Cell Therapy for COVID-19: Present or Future Preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cell-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. [Stem Cell Rev Rep] Abstract Visit our reviews page to see a complete list of reviews in the cell therapy research field. |
|
|
|
|
INDUSTRY NEWSWindMIL Therapeutics announced it has begun enrollment in the combination therapy portion of its open-label, multi-center Phase IIa clinical trial to assess the safety and efficacy of MILs in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to, or have relapsed on, an anti-PD-1-containing regimen. [WindMIL Therapeutics (GlobeNewswire, Inc.)] Press Release Novartis announced that the FDA granted Regenerative Medicine Advanced Therapy designation to Kymriah®, for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma. Kymriah, which is designed to be a one-time treatment, is the first-ever FDA-approved CAR-T cell therapy. [Novartis] Press Release CARsgen Therapeutics Co., Ltd. announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products adopted a positive opinion on CARsgen’s application for orphan designation of its investigational CT053 CAR T-cell therapy, fully human anti-B cell maturation antigen (BCMA) autologous CAR T cells for the treatment of multiple myeloma. [CARsgen Therapeutics Co., Ltd. (PR Newswire Asia Ltd.)] Press Release Mustang Bio, Inc. announced that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease. [Mustang Bio, Inc.] Press Release Citius Pharmaceuticals, Inc. announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research of the FDA under the Coronavirus Treatment Acceleration Program. [Citius Pharmaceuticals, Inc.] Press Release | |
|
|
|
POLICY NEWSOpen Science Takes On the Coronavirus Pandemic When reports emerged in late 2019 of an outbreak of a new coronavirus centred in Wuhan, China, researchers at the virological-analysis website Nextstrain were ready. The open-source project tracks the spread of viruses through genetic variations in the sequences that scientists find. [Nature News] Editorial Untapped Potential: More US Labs Could Be Providing Tests for Coronavirus A survey of more than 4,000 researchers in the United States suggests that better coordination at an institutional and national level could make hundreds of thousands more tests for coronavirus available. [Nature News] Editorial
|
|
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
|
|
JOB OPPORTUNITIESNEW Lab Director – Cancer Immunotherapy (Vrije Universiteit Brussel) Postdoctoral Fellow – Cancer Drug Discovery (Uniformed Services University of Health Sciences) Scientist – Cancer Immunotherapy (Vrije Universiteit Brussel) Postdoctoral Associate – Diabetes (University of Miami Health System) Associate/Senior Editor – Nature Biotechnology (Nature Research) Team Leaders – Stem Cell Biology (RIKEN Center for Biosystems Dynamics Research) Professorship – Biological Therapies of the Inner Ear (Hannover Medical School) Group leaders – Cancer Biology (Institute of Pharmacology and Structural Biology) Scientist – Cancer Immunotherapy (Lund University) Postdoctoral Position – Cancer Immunotherapy (The University of Texas MD Anderson Cancer Center) Sr Associate Scientist – Autoimmunity and Tumor Immunotherapy (Amgen)
Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
|
|
|
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. |
|
|

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News



